Article
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 1 Nov 2020
Nazha Aziz, Hu Zhen-Huan, Wang Tao, Lindsley R Coleman, Abdel-Azim Hisham, Aljurf Mahmoud, Bacher Ulrike, Bashey Asad, Cahn Jean-Yves, Cerny Jan, Copelan Edward, DeFilipp Zachariah, Diaz Miguel Angel, Farhadfar Nosha, Gadalla Shahinaz M, Gale Robert Peter, George Biju, Gergis Usama, Grunwald Michael R, Hamilton Betty, Hashmi Shahrukh, Hildebrandt Gerhard C, Inamoto Yoshihiro, Kalaycio Matt, Kamble Rammurti T, Kharfan-Dabaja Mohamed A, Lazarus Hillard M, Liesveld Jane L, Litzow Mark R, Majhail Navneet S, Murthy Hemant S, Nathan Sunita, Nishihori Taiga, Pawarode Attaphol, Rizzieri David, Sabloff Mitchell, Savani Bipin N, Schachter Levanto, Schouten Harry C, Seo Sachiko, Shah Nirav N, Solh Melhem, Valcárcel David, Vij Ravi, Warlick Erica, Wirk Baldeep, Wood William A, Yared Jean A, Alyea Edwin, Popat Uday, Sobecks Ronald M, Scott Bart L, Nakamura Ryotaro, Saber Wael
Abstract excerpt
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes (MDS). Mortality after HCT is high, with deaths related to relapse or transplant-related complications. Thus, identifying patients who may or may not benefit from HCT is clinically important. We identified 1514 patients with MDS enrolled in the Center for International Blood and...
Read the complete abstract on PubMed